Blood Purification Equipment Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2021
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Blood Purification Equipment is to filter blood by removing the irreversibly damaged red blood cells and toxins before transfusion and reduces the occurrence of post-transfusion complications. The report provides comprehensive information about the blood purification equipment pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
What are the market dynamics in the blood purification equipment pipeline products?
As of November 2021, 2 pipeline products were in the approval process and 14 pipeline products were in the inactive stage. 17 pipeline products were in the pre-clinical stage and 19 pipeline products were in the clinical stage. 2 pipeline products were in the intermediate stage and only one product was found to be discontinued. The US is the leading geographic region for the blood purification equipment pipeline products with 38 pipeline products followed by Europe, Japan, China, the UK, Canada, France, Germany, Poland, Turkey, and Israel. There were 13 planned trials, 38 ongoing, recruiting trials, and 1 is ongoing, recruiting by invitation.
Which are the key players in the blood purification equipment pipeline products market?
The key players in the market are Accel Diagnostics LLC, Advanced Prenatal Therapeutics, Inc., Aethlon Medical Inc, Asahi Kasei Medical Co Ltd, Avalon GloboCare Corp, Boston Children’s Hospital, Cala Medical Ltd, Cerus Corp, Chemofilter Inc (Inactive), CytoSorbents Corp and EBO2 Inc.
Company overview:
Accel Diagnostics LLC: Accel Diagnostics LLC (Accel Diagnostics), formerly Tropical Health Systems LLC, is a medical diagnostics technology developer company. The company offers pScreen disposable test for a variety of medical conditions and pScreen-BNP blood test for diagnosis and monitoring of congestive heart failure patients with a mobile-connected pScreen device. It is also involved in the development of diagnostics of sepsis and concussion.
The product is mPharesis that is a portable dialysis-like blood purification device intended for the treatment of malaria. It is designed to remove the malaria-infected red blood cells from the patient s blood. It is based on Magnetic Separation Technology. It works by passing an extremely thin layer of blood over an array of magnets and ferromagnetic wires.
Aethlon Medical Inc: Aethlon Medical Inc (Aethlon Medical) is a developer of therapeutic technologies that address unmet needs in biodefense and global health. The company’s lead product Hemopurifier is a clinical-stage immunotherapeutic device designed to single-use removal of life-threatening viruses and exosomes from the human circulatory system that promote immune suppression. Aethelon Medical received Breakthrough Device designation from the US FDA for the treatment of life- threatening viruses with no approved therapies and for the treatment of individuals with metastatic cancer who are unresponsive to standard of care therapy. Aethlon Medical is headquartered in San Diego, California, the US.
The product is ASEPSYS Device (Anticoagulation-Free Anti-Sepsis Extracorporeal System) that is a dialysis-like device intended for hemoperfusion. It is designed to selectively clear multiple sepsis-enabling particles from blood circulation to promote recovery and prevent sepsis. It is based on Aethlon ADAPT System Technology.
Asahi Kasei Medical Co Ltd: Asahi Kasei Medical Co Ltd (Asahi Kasei), a subsidiary of Asahi Kasei Corp develops, is a medical device company. The company manufactures and commercializes medical device systems for blood treatment and purification based on advanced membrane separation and adsorption technologies. It’s product portfolio includes dialyzers (artificial kidneys) for hemodialysis treatment leukocyte reduction filters for blood transfusion therapeutic apheresis products and virus removal filters.
The product is ASEPSYS Device (Anticoagulation-Free Anti-Sepsis Extracorporeal System) that is a dialysis-like device intended for hemoperfusion. It is designed to selectively clear multiple sepsis-enabling particles from blood circulation to promote recovery and prevent sepsis. It is based on Aethlon ADAPT System Technology.
Boston Children’s Hospital: Boston Children’s Hospital (Boston Children’s) is a paediatric medical centre that provides a comprehensive range of health care services for children from birth through 21 years of age. Boston Children’s is the primary paediatric teaching affiliate of Harvard Medical School. The organization provides specialty services such as cardiovascular surgery, digestive care, blood diseases, fetal care, and others. Its Advanced Fetal Care Centre supports the needs of families and referring physicians at all steps of care for various congenital anomalies, from diagnosis and counselling through treatment and follow-up. It collaborates with other institutes such as Harvard Stem Cell Institute, MIT Health Sciences & Technology, the Broad Institute, the Autism Consortium and Boston University. Boston Children’s is headquartered in Boston, Massachusetts, the US.
Its blood filtration device is intended for the management of sepsis. It is designed to filter specific cytokines from circulating blood. It helps to understand the complex interplay of different cytokines and enables the removal of cytokines responsible for that person’s unique inflammatory response.
Cerus Corp: Cerus Corp (Cerus) is a biomedical products company that focuses on the field of blood transfusion safety. It develops and commercializes Intercept blood system, which reduces the risk of transfusion-transmitted infections by inactivating a wide range of pathogens including viruses, bacteria and parasites present in donated blood. The Intercept blood system is for use with blood components including platelets, plasma, and red blood cells. It is also used to produce PRCFC, and pathogen reduced plasma and cryoprecipitate. The company markets and sells the Intercept blood system through its direct sales force and distributors in several countries including the US, Europe, the Commonwealth of Independent States (CIS), Latin America, the Middle East, and selected countries in other regions. Cerus is headquartered in Concord, California, the US.
CytoSorbents Corp: CytoSorbents Corp (CytoSorbents), formerly MedaSorb Technologies Corp, is a critical care immunotherapy company that develops blood purification products. Its flagship product, CytoSorb is an extracorporeal cytokine adsorber that is designed to control extreme systemic inflammation in seriously ill patients by reducing excessive cytokines and bacterial toxins. CytoSorbents’ CytoSorb is also being administered during and after cardiac surgery to prevent post-operative complications such as multiple organ failure. The company offers VetResQ, a blood purification adsorber, to support and treat excessive inflammation and toxic injury in animals. The company offers its products through a network of distributors across Europe, the Middle East and Asia Pacific.
Blood purification equipment pipeline products market, by key players
To know more about key players, download a free report sample
Market report scope
| Key countries/regions | The US, Europe, Japan, China, the UK, Canada, France, Germany, Poland, Turkey, and Israel |
| Key players | Accel Diagnostics LLC, Advanced Prenatal Therapeutics, Inc., Aethlon Medical Inc, Asahi Kasei Medical Co Ltd, Avalon GloboCare Corp, Boston Children’s Hospital, Cala Medical Ltd, Cerus Corp, Chemofilter Inc (Inactive), CytoSorbents Corp, EBO2 Inc, Eliaz Therapeutics Inc, Ex Vivo Dynamics Inc, ExThera Medical Corp, Filtro Medical Inc, Good SIRS, HemoTune AG, Immunicom Inc, JIMRO Co Ltd, Kohane Lab, Leukocare AG, McGowan Institute for Regenerative Medicine, MediSieve Ltd, Miltenyi Biotec BV & Co KG, Nipro Corpc, Nonwovens Innovation & Research Institute Ltd, NuVascular Technologies Inc, NxStage Medical Inc, Opsonix Inc, Pall Medical Products Inc, Path Ex Inc, ProSorp BioTech Inc, Pure Biologics SA, Recombinant Technologies LLC, SanSepsis BV, Santersus AG, Sigyn Therapeutics Inc, Toray Medical Co Ltd, University of Louisville, Viatar CTC Solutions Inc, and Zata Pharmaceuticals Inc. |
Scope
- Extensive coverage of the blood purification equipment under development.
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities.
- The report reviews the major players involved in the development of Blood Purification Equipment and list all their pipeline projects.
- The coverage of pipeline products based on various stages of development ranging from Early Development to the Approved/Issued stage.
- The report provides key clinical trial data of ongoing trials specific to pipeline products.
- Recent developments in the segment/industry.
Reasons to Buy
The report enables you to:
- Formulate significant competitor information, analysis, and insights to improve R&D strategies.
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage.
- Identify and understand important and diverse types of Blood Purification Equipment under development.
- Develop market-entry and market expansion strategies.
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline.
- In-depth analysis of the product’s current stage of development, territory, and estimated launch date.
Advanced Prenatal Therapeutics, Inc.
Aethlon Medical Inc
Asahi Kasei Medical Co Ltd
Avalon GloboCare Corp
Boston Children's Hospital
Cala Medical Ltd
Cerus Corp
Chemofilter Inc (Inactive)
CytoSorbents Corp
EBO2 Inc
Eliaz Therapeutics Inc
Ex Vivo Dynamics Inc
ExThera Medical Corp
Filtro Medical Inc
Good SIRS
HemoTune AG
Immunicom Inc
JIMRO Co Ltd
Kohane Lab
Leukocare AG
McGowan Institute for Regenerative Medicine
MediSieve Ltd
Miltenyi Biotec BV & Co KG
Nipro Corp
Nonwovens Innovation & Research Institute Ltd
NuVascular Technologies Inc
NxStage Medical Inc
Opsonix Inc
Pall Medical Products Inc
Path Ex Inc
ProSorp BioTech Inc
Pure Biologics SA
Recombinant Technologies LLC
SanSepsis BV
Santersus AG
Sigyn Therapeutics Inc
Toray Medical Co Ltd
University of Louisville
Viatar CTC Solutions Inc
Zata Pharmaceuticals Inc
Table of Contents
Frequently asked questions
-
Which are the key regions in the blood purification equipment pipeline products market?
The US is the leading market followed by Europe, Japan, China, the UK, Canada, France, Germany, Poland, Turkey, and Israel.
-
Which are the key players in the blood purification equipment pipeline products market?
The key players in the market are Accel Diagnostics LLC, Advanced Prenatal Therapeutics, Inc., Aethlon Medical Inc, Asahi Kasei Medical Co Ltd, Avalon GloboCare Corp, Boston Children’s Hospital, Cala Medical Ltd, Cerus Corp, Chemofilter Inc (Inactive), CytoSorbents Corp and EBO2 Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
Blood Purification Equipment Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2021 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
